Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity
Rambam Maimonides Medical Journal · 26.10.2026 · 17 (4) · e0024
DOI: 10.5041/rmmj.10585 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rambam Maimonides Medical Journal, online erschienen am 26.10.2026. Verfasst von Het Tushar Jani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Master of Public Health Program, Long Island University, Brooklyn, New York, USA. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Neuropsychiatric safety concerns about glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and tirzepatide prompted regulatory review by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). We synthesized the contemporary evidence in adults with type 2 diabetes mellitus or obesity, emphasizing study design, risk of bias, and the distinction between signal detection and causal inference.
Methods
The PubMed/MEDLINE, Embase, Web of Science, and Scopus databases were searched without a lower date limit through March 15, 2026 (English, adults ≥18 years). The review was reported with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020, and the PRISMA-S and PRISMA-Harms extensions. Evidence was grouped into prespecified categories: randomized syntheses, comparative observational studies and target-trial emulations, outlier non-active-comparator studies, pharmacovigilance analyses, and regulatory reviews. Risk of bias was appraised with the Cochrane Risk of Bias 2 tool and with Risk of Bias in Non-randomised Studies of Interventions; certainty was summarized using Grading of Recommendations Assessment, Development and Evaluation.
Results
Twenty studies and two regulatory reviews met the inclusion criteria. Randomized evidence, including two large 2025 meta-analyses and post hoc pooled analyses of semaglutide and tirzepatide, showed no increased risk of suicidality, depression, or anxiety, though psychiatric exclusion criteria limited generalizability. Active-comparator cohorts from the United States, Scandinavia, and the United Kingdom likewise showed no clear increase after confounding control. Passive-comparator and disproportionality analyses generated signals but could not separate drug effects from baseline psychiatric risk, obesity-related distress, or reporting bias. The EMA and FDA conclusions do not support a causal class-wide association between GLP-1 RAs and suicidal ideation or behavior.
Conclusions
Evidence does not support a clinically meaningful increase in neuropsychiatric harm with GLP-1 RAs or tirzepatide in the populations studied. Surveillance remains warranted for patients with substantial psychiatric morbidity, for obesity-only populations, and for long-term rare outcomes.
Autor:innen und Institutionen
- Master of Public Health Program, Long Island University, Brooklyn, New York, USA.
- Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
- St. Vincent's Medical Center, Hartford HealthCare, Bridgeport, Connecticut, USA.
Zitieren
APA
Jani, H. T., Levine, H., Patel, A., Trivedi, R., & Patel, X. D. (2026). Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity. Rambam Maimonides Medical Journal, 17(4), e0024. https://doi.org/10.5041/rmmj.10585
Vancouver
Jani HT, Levine H, Patel A, Trivedi R, Patel XD. Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity. Rambam Maimonides Medical Journal. 2026;17(4):e0024. doi:10.5041/rmmj.10585
BibTeX
@article{Jani2026,
author = {Jani, Het Tushar and Levine, Helisse and Patel, Abhiraj and Trivedi, Richa and Patel, Xitij Dineshkumar},
title = {Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity},
journal = {Rambam Maimonides Medical Journal},
year = {2026},
volume = {17},
number = {4},
pages = {e0024},
doi = {10.5041/rmmj.10585}
}
EUVIMED